---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-031438"
form_type: "8-K"
ticker: "LYRA"
cik: "0001327273"
company_name: "Lyra Therapeutics, Inc."
filed_at: "2022-09-12T23:59:59+00:00"
generated_at: "2026-06-23T10:48:45.930159+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "low"
source: SEC EDGAR
---

# Lyra presents additional Phase 2 LANTERN data for LYR-210 at ARS meeting

## Summary
- Posted slide presentation with additional Phase 2 results from LANTERN trial of LYR-210 for chronic rhinosinusitis.
- Data presented at 68th Annual Meeting of the American Rhinologic Society on September 10, 2022.
- Top-line results from LANTERN previously reported on April 11, 2021; this update includes further analysis.
- Slide deck available on Lyra's investor website and attached as exhibit to the 8-K.

## SEC filing metadata
- accession: 0001564590-22-031438
- form_type: 8-K
- ticker: LYRA
- cik: 0001327273
- company_name: Lyra Therapeutics, Inc.
- filed_at: 2022-09-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1327273/000156459022031438/0001564590-22-031438-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1327273/000156459022031438/lyra-8k_20220910.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-031438
- JSON: https://secwatch.observer/filing/0001564590-22-031438.json
- Plain text: https://secwatch.observer/filing/0001564590-22-031438.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.